CD8A and thymoma: Since MSC-TPr can efficiently uptake and process soluble OVA, yet are unable to activate CD8 T cells in vitro, we next interrogated their therapeutic utility against the E.G7 (OVA-expressing EL4 thymoma) T-cell lymphoma model (Figure 5A).